Public Policy: An Analgesia for Opioid Diversion

References

• Brushwood DB, Rich BA, Coleman JJ, Bolen J, Wong W. Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain. J Pain Palliat Care Pharmacother. 2010;24(4):333–48. doi:10.3109/15360288.2010.524979.
   PubMedGoogle Scholar
• Wood D. Drug diversion. Aust Prescr. 2015;38(5):164–6.
   PubMed Web of Science ®Google Scholar
• Inciardi JA, Surratt HL, Cicero TJ, Kurtz SP, Martin SS, Parrino MW. The "black box" of prescription drug diversion. J Addict Dis. 2009;28(4):332–47.
   PubMed Web of Science ®Google Scholar
• McGregor C, Gately NJ, Fleming JR. Prescription drug use among detainees: prevalance, sources and links to crime. Trends Issues in Crime and Criminal Justice 2011;423:1–6.
   Google Scholar
• Turk DC, Rudy TE. IASP taxonomy of chronic pain syndromes: preliminary assessment of reliability. Pain 1987;30(2):177–89.
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012;380(9859):2163–96. doi:10.1016/S0140-6736(12)61729-2.
   PubMed Web of Science ®Google Scholar
• Reid KJ, Harker J, Bala MM, Truyers C, Kellen E, Bekkering GE, Kleijnen J. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin. 2011;27(2):449–62. doi:10.1185/03007995.2010.545813.
   PubMed Web of Science ®Google Scholar
• Marcus DA. Epidemiology of cancer pain. Curr Pain Headache Rep. 2011;15(4):231–4.
   PubMed Web of Science ®Google Scholar
• Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16(8):769–80.
   PubMed Web of Science ®Google Scholar
• Melnikova I. Pain market. Nat Rev Drug Discov. 2010;9(8):589–90.
   PubMed Web of Science ®Google Scholar
• Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;2010(1):Cd006605.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA 2016;315(15):1624–45. doi:10.1001/jama.2016.1464.
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2016;4:Cd003868.
   PubMedGoogle Scholar
• Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol. 2016;82(1):255–67.
   PubMed Web of Science ®Google Scholar
• Joranson DE, Gilson AM, Dahl JL, Haddox JD. Pain management, controlled substances, and state medical board policy: a decade of change. J Pain Symptom Manage. 2002;23(2):138–147.
   PubMed Web of Science ®Google Scholar
• Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA 2000;284(4):428–9.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Helm S, 2nd, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician. 2012;15(3):ES9–38.
   PubMed Web of Science ®Google Scholar
• Inciardi JA, Surratt HL, Cicero TJ, Beard RA. Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment. Pain Med. 2009;10(3):537–48. doi:10.1111/j.1526-4637.2009.00603.x.
   PubMed Web of Science ®Google Scholar
• Ensuring Availability of Controlled Medications for the Relief of Pain and Preventing Diversion and Abuse: Striking the Right Balance to Achieve the Optimal Public Health Outcome. Commission on Narcotic Drugs; 2011; Vienna: United Nations Office on Drugs and Crime,.
   Google Scholar
• Dart RC, Severtson SG, Bucher-Bartelson B. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(16):1573–74.
   PubMed Web of Science ®Google Scholar
• Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother. 2010;24(2):141–4.
   PubMedGoogle Scholar
• Addressing Prescription Drug Abuse in the United States: current Activities and Future Opportunities. Atlanta: Centers for Disease Control and Prevention: U.S. Department of Health and Human Services;2013.
   Google Scholar
• United States v. Moore, 423 (U.S. Supreme Court 1975).
   Google Scholar
• Rigg KK, Kurtz SP, Surratt HL. Patterns of prescription medication diversion among drug dealers. Drugs (Abingdon, England) 2012;19(2):144–55.
   PubMedGoogle Scholar
• Guevremont N, Barnes M, Haupt CE. Physician autonomy and the opioid crisis. J Law Med Ethics. 2018;46(2):203–19. doi:10.1177/1073110518782922.
   PubMed Web of Science ®Google Scholar
• Webster LR, Grabois M. Current regulations related to opioid prescribing. PM & R: J Inj, Funct, Rehabilitat. 2015;7(11):S236–S47. doi:10.1016/j.pmrj.2015.08.011.
   PubMedGoogle Scholar
• Rutkow L, Chang HY, Daubresse M, Webster DW, Stuart EA, Alexander GC. Effect of Florida's prescription drug monitoring program and Pill Mill Laws on opioid prescribing and use. JAMA Intern Med. 2015;175(10):1642–9. doi:10.1001/jamainternmed.2015.3931.
   PubMed Web of Science ®Google Scholar
• Lyapustina T, Rutkow L, Chang H-Y, Daubresse M, Ramji AF, Faul M, Stuart EA, Alexander GC. Effect of a “Pill Mill” law on opioid prescribing and utilization: the case of Texas. Drug Alcohol Depend. 2016;159:190–7. doi:10.1016/j.drugalcdep.2015.12.025.
   PubMed Web of Science ®Google Scholar
• Gilson AM, Joranson DE, Maurer MA, Ryan KM, Garthwaite JP. Progress to achieve balanced state policy relevant to pain management and palliative care: 2000-2003. J Pain Palliat Care Pharmacother. 2005;19(1):13–26.
   PubMedGoogle Scholar
• Brennan F. The US congressional "decade on pain control and research" 2001-2011: a review. J Pain Palliat Care Pharmacother. 2015;29(3):212–27.
   PubMedGoogle Scholar
• Schmidt C. Experts worry about chilling effect of federal regulations on treating pain. J Natl Cancer Inst. 2005;97(8):554–5. doi:10.1093/jnci/97.8.554.
   PubMedGoogle Scholar
• Dispensing Controlled Substances for the Treatment of Pain. In: Justice USDo, editor. Vol 71. Washington, DC: Federal Register Online via GPO Access; 2006:52715–23.
   Google Scholar
• Issuance of multiple prescriptions for schedule II controlled substances. Final rule. Fed Reg. 2007;72(222):64921–30.
   PubMedGoogle Scholar
• Reidenberg MM, Willis O. Prosecution of physicians for prescribing opioids to patients. Clin Pharmacol Ther. 2007;81(6):903–6.
   PubMed Web of Science ®Google Scholar
• Goldenbaum DM, Christopher M, Gallagher RM, Fishman S, Payne R, Joranson D, Edmondson D, McKee J, Thexton A. Physicians charged with opioid analgesic-prescribing offenses. Pain Med. 2008;9(6):737–47. doi:10.1111/j.1526-4637.2008.00482.x.
   PubMed Web of Science ®Google Scholar
• Rannazzisi JT. The DEA's balancing act to ensure public health and safety. Clin Pharmacol Ther. 2007;81(6):805–6.
   PubMed Web of Science ®Google Scholar
• Gibbs LS, Haddox JD. Lawful prescribing and the prevention of diversion. J Pain Palliat Care Pharmacother. 2003;17(1):5–14.
   PubMedGoogle Scholar
• Carnevale JT, Kagan R, Murphy PJ, Esrick J. A practical framework for regulating for-profit recreational marijuana in US States: lessons from Colorado and Washington. Int J Drug Policy. 2017;42:71–85.
   PubMed Web of Science ®Google Scholar
• Berge KH, Dillon KR, Sikkink KM, Taylor TK, Lanier WL. Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention. Mayo Clin Proc. 2012;87(7):674–82. doi:10.1016/j.mayocp.2012.03.013.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–66.
   PubMed Web of Science ®Google Scholar
• Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23(12):1238–46. doi:10.1002/pds.3658.
   PubMed Web of Science ®Google Scholar
• Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis. 2007;26(3):107–11.
   PubMed Web of Science ®Google Scholar
• Hale ME, Moe D, Bond M, Gasior M, Malamut R. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016;6(5):497–508. doi:10.2217/pmt-2015-0005.
   PubMed Web of Science ®Google Scholar
• FDA Requests Removal of Opana ER for Risks Related to Abuse [Press Release]. Silver Spring: U.S. Food and Drug Administration 2017.
   Google Scholar
• Skaer TL, Nwude AC. Opioid prescribing laws and emergency department guidelines for chronic non-cancer pain in Washington State. Pain Pract. 2016;16(5):642–7. doi:10.1111/papr.12359.
   PubMed Web of Science ®Google Scholar
• California Business and Professional Code. Sections 2190.5, 2241.6 and 23132004.
   Google Scholar
• Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician. 2009;12(3):507–15.
   PubMed Web of Science ®Google Scholar
• Laws NAfMSD. Model Alcohol and Other Drug Abuse Policy and Planning Coordination Act. In:, ed. Charlottesville, VA.
   Google Scholar
• Cheung CW, Qiu Q, Choi SW, Moore B, Goucke R, Irwin M. Chronic opioid therapy for chronic non-cancer pain: a review and comparison of treatment guidelines. Pain Physician. 2014;17(5):401–14.
   PubMed Web of Science ®Google Scholar
• Chaverneff F. CDC Guideline on prescribing opioids: some major concerns. Clinical Pain Advisor; 2017.
   Google Scholar
• Cobaugh DJ, Gainor C, Gaston CL, Kwong TC, Magnani B, McPherson ML, Painter JT, Krenzelok EP. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems. Am J Health Syst Pharm. 2014;71(18):1539–54. doi:10.2146/ajhp140157.
   PubMed Web of Science ®Google Scholar
• Foley KM, Fins JJ, Inturrisi CE. A true believer's flawed analysis. Arch Intern Med. 2011;171(9):867–8; author reply 868.
   PubMedGoogle Scholar
• Volkow ND, McLellan AT. Opioid abuse in chronic pain-misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–1263.
   PubMed Web of Science ®Google Scholar
• Olsen Y. The CDC guideline on opioid prescribing: rising to the challenge. JAMA 2016;315(15):1577–79.
   PubMed Web of Science ®Google Scholar
• Teo WZ, Bal BS. The law and social values: prescription pain killers. Clin Orthop Relat Res. 2016;474(9):1924–29.
   PubMed Web of Science ®Google Scholar
• Gabay M. The federal controlled substances act: schedules and pharmacy registration. Hospital Pharmacy. 2013;48(6):473–4. doi:10.1310/hpj4806-473.
   PubMedGoogle Scholar
• Gottlieb S, Woodcock J. Marshaling FDA benefit-risk expertise to address the current opioid abuse epidemic. JAMA 2017;318(5):421–422.
   PubMed Web of Science ®Google Scholar
• Califf RM, Woodcock J, Ostroff S. A proactive response to prescription opioid abuse. N Engl J Med. 2016;374(15):1480–1485.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services (HHS) OotSG. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, Executive Summary. Washington, DC: HHS; 2016.
   Google Scholar
• Murthy VH. Ending the opioid epidemic - a call to action. N Engl J Med. 2016;375(25):2413–5.
   PubMed Web of Science ®Google Scholar
• Williams AR, Bisaga A. From AIDS to opioids - how to combat an epidemic. N Engl J Med. 2016;375(9):813–5.
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend. 1996;43(3):191–8.
   PubMed Web of Science ®Google Scholar
• Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol. 2014;78(5):1159–66.
   PubMed Web of Science ®Google Scholar
• Bell J. The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective. Addiction (Abingdon, England). 2010;105(9):1531–7. doi:10.1111/j.1360-0443.2010.03014.x.
   PubMedGoogle Scholar
• Degenhardt L, Bruno R, Ali R, Lintzeris N, Farrell M, Larance B. The introduction of a potentially abuse deterrent oxycodone formulation: early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug Alcohol Depend. 2015;151:56–67. doi:10.1016/j.drugalcdep.2015.02.038.
   PubMed Web of Science ®Google Scholar
• Larance B, Degenhardt LJ, Mattick RP, O’Brien S, Lintzeris N, Bell J, Winstock A, Ali R. The Diversion and Injection of the Pharmaceutical Opioids Used in Opiod Substitution Treatment: Findings from the Australian Post-Marketing Surveillance Studies of Buprenorphine-Naloxone, 2006-2008. Sydney: National Drug and Alcohol Research Centre.;2009.
   Google Scholar
• National Pharmaceutical Drug Misuse Framework for Action (2012-2015): A Matter of Balance. In: Strategy ND, ed. Canberra: Australian Capital Territory 2011.
   Google Scholar